Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

Video

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

David Albala, MD, chief of urology, Crouse Hospital, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

The sensitivity and specificity of PSMA-PET scans are superior to that of current modalities used to identify prostate cancer, Albala says. These conventional imaging techniques, such as bone scans or CT scans, and the more recently developed fluciclovine (Axumin)-PET/CT scan have all contributed to advancements in this imaging technology.

Ultimately, PSMA-PET scans show promising diagnostic performance, and could completely change the current landscape of prostate cancer imaging. Moving forward, clinicians should aim to understand what this exciting new technology entails and consider how to best incorporate it into their current treatment strategies, Albala concludes.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD